GE and Danaher Get FTC Clearance for BioPharma Deal
The U.S. Federal Trade Commission (FTC) has cleared the path for the sale of General Electric Co.'s (NYSE: GE) BioPharma unit to Danaher Corp. (NYSE: DHR). The deal was announced in February, 2019. Danaher is a medical company that operates in three segments: life sciences, diagnostics, and environmental & applied solutions.
In a joint statement, the companies announced that signing the consent decree with the FTC has satisfied all needed antitrust requirements, and the deal is expected to close at the end of the month. In addition to the FTC, the statement said the deal has been cleared by the European Commission as well as antitrust authorities from six other countries, including China, Brazil and Israel.
Image source: Getty Images.
Source Fool.com
